Philips previews Titanion MR for quantitative 3T imaging

Philips has introduced Titanion MR, an ultra-high-gradient 3T MRI system designed to support quantitative and biologically informative imaging.

The company unveiled the system at the ISMRM 2026 annual meeting in Cape Town, South Africa. Philips said Titanion MR is intended to move MRI beyond anatomical and functional imaging by supporting biomarkers that reflect tissue microstructure and underlying biological processes.

Titanion MR offers ultra-high gradient performance of 150 mT/m at a slew rate of 250 T/m/s, according to Philips. The system also features a 55-cm field of view for whole-body coverage and a low eddy-current design intended to reduce distortion in quantitative measurements.

The platform is aimed at advanced microstructural imaging and biomarker development across the body, with Philips highlighting potential applications in neurology and oncology. In those areas, more quantitative MRI data may help researchers and clinicians characterize tissue beyond conventional structural imaging.

SmartSpeed Precise is part of the system’s software approach. Philips said the dual-AI reconstruction technology can improve image sharpness by up to 80% and increase scan speed by up to 3 times compared with conventional imaging.

“Titanion MR represents a significant step forward for 3.0T MRI at Philips,” said Ioannis Panagiotelis, business leader for magnetic resonance at Philips.

The company said Titanion combines ultra-high gradient performance with AI-enabled workflows. That combination is intended to help clinicians and researchers generate more precise and reproducible quantitative results, particularly for tissue microstructure and biologically relevant imaging markers.

The system was presented alongside Philips’ ISMRM 2026 portfolio. Philips also highlighted BlueSeal Horizon, described by the company as a helium-free 3T MRI platform, as part of its conference presence.

Titanion MR is not yet commercially available. Philips said the system is a work in progress and is not CE-marked or available for sale in any jurisdiction.

For MRI departments and research centers, the announcement points to continued vendor investment in high-performance 3T systems that can support quantitative MRI, faster reconstruction, and disease-monitoring applications. The practical value will depend on future validation, regulatory clearance, availability, and whether biomarker-focused MRI workflows can be integrated into routine clinical operations.

The system’s clinical impact therefore remains prospective. For now, the news is mainly a technology and conference milestone, not a commercial launch.